Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578266 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00578266: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00578266 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00578266, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
For patients with severe aplastic anemia (SAA) who have failed to respond to immunosuppressive therapy and lack an HLA identical family member, our objectives are to make an initial assessment of the safety and efficacy of allogenic stem cell transplantation from either a matched unrelated donor or a mismatched reacted donor using the conditioning regimen of Cytoxan, reduced total body irradiation (TBI) and Campath IH. The principle measures of safety and efficacy will be : 1. Patient survival probability at 100 days, 1 year and 2 years. 2. Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and chronic GVHD within 6 months and 2 years. 3. Engraftment at 6 months, 1 year and 2 years
Interventions
- DRUG Cyclophosphamide,Campath IH and TBI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-02 |
| Est. Completion | 2016-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00578266
The ClinicalTrials.gov registry entry for NCT00578266 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cyclophosphamide,Campath IH and TBI is the first listed.
NCT00578266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00578266 about?
NCT00578266 is a clinical study titled "Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia". For patients with severe aplastic anemia (SAA) who have failed to respond to immunosuppressive therapy and lack an HLA identical family member, our objectives are to make an initial assessment of the safety and efficacy of allogenic stem cell transplantation from either a matched unrelated donor or ...
What is the current status of trial NCT00578266?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2007-02. Estimated completion is 2016-08-16.
What interventions are being tested in trial NCT00578266?
The interventions under investigation include: Cyclophosphamide,Campath IH and TBI (DRUG).
Who is sponsoring clinical trial NCT00578266?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.